ArticleInsights into imaging2026
Amygdala volume is not associated with MRI-based markers of early cardiovascular disease.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent PET studies suggest a link between amygdala activity and cardiovascular disease. Altered amygdala volumes are associated with increased stressor-evoked cardiovascular reactivity, which potentially increases the risk for cardiovascular disease. Therefore, we investigated the association between amygdala volume and MRI-based markers of cardiovascular disease in order to evaluate morphological alterations of the amygdala in persons with early, clinically inapparent signs of cardiovascular complications. MATERIALS AND
methods400 subjects underwent a comprehensive 3-T MRI to estimate amygdala volume and imaging-based markers of cardiovascular disease, specifically carotid plaque presence and grading, media wall thickening, left ventricular myocardial mass, myocardial late gadolinium enhancement, and left ventricular function. Amygdala volume was automatically segmented based on FLAIR images and corrected for total intracranial volume. Logistic and linear regression analyses of amygdala volume and cardiovascular parameters were conducted while controlling for age, gender and cardiovascular risk factors.
resultsAmong 339 included subjects (mean age: 56.3 ± 9.1, 57% males), the average absolute amygdala volume was 3.04 ± 0.24 mL, and the average amygdala ratio was 0.213 ± 0.017% of total intracranial volume. Carotid plaque was present in 22.6%, and myocardial late gadolinium enhancement in 3.2%. Mean media wall thickening was 0.76 ± 0.1 mm, mean left ventricular myocardial mass 71.6 ± 14.1 g/m
conclusionsAmygdala volume was not associated with early MRI-based markers of cardiovascular disease, suggesting that the amygdala is not morphologically altered in the initial phase of cardiovascular disease. CRITICAL RELEVANCE STATEMENT: This first large MRI study demonstrates that amygdala volume is not associated with subclinical cardiovascular disease, critically refining prior PET-based hypotheses and advancing clinical radiology by clarifying the preserved role of amygdala morphology in early cardiovascular pathology. KEY POINTS: PET studies link amygdala activity to cardiovascular disease, while the role of amygdala volume in early cardiovascular disease is unclear. In this large population-based study, 339 asymptomatic adults who underwent comprehensive 3-T MRI with cardiovascular assessment were analyzed. Amygdala volume showed no association with MRI markers of subclinical cardiovascular disease. This is the first large MRI study linking amygdala volume and early cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.